Media

Corgentech Presents Preclinical Data Demonstrating Reduction of Inflammation Using New Drug Candidate for Inflammatory Bowel Disease

SOUTH SAN FRANCISCO, Calif., June 27, 2005 /PRNewswire-FirstCall via COMTEX/ -- Corgentech Inc. (Nasdaq: CGTK) today announced that its NF-kappaB Decoy (NF-kappaB Decoy) drug candidate was effective in preclinical studies in reducing disease activity in acute and chronic models of Crohn's disease and ulcerative colitis-both also referred to as inflammatory bowel disease (IBD). NF-kappaB Decoy was shown to be efficiently delivered to inflamed areas of the gut, significantly reduced inflammatory cell infiltrates and expression of proinflammatory genes, and reversed disease-associated weight loss and tissue damage in multiple chronic and acute preclinical models of IBD. These data were presented today at the 12th International Congress of Mucosal Immunology in Boston, MA.

These data further corroborate preclinical data presented last month which showed NF-kappaB Decoy's ability to dramatically decrease inflammation and swelling in preclinical models of atopic dermatitis, a chronic inflammatory skin disease also known as eczema. Corgentech is currently conducting a multi-center, Phase 1/2 clinical trial of NF-kappaB Decoy for eczema in the United States involving approximately 75 patients, and a second trial of approximately 120 patients will begin enrolling patients imminently and will be conducted in Australia and Switzerland. The company has not yet forecasted its plans relating to a clinical trial for IBD.

NF-kappaB Decoy is a selective and potent inhibitor of the transcription factor NF-kappaB, which is implicated in inflammatory diseases such as eczema, asthma and IBD.

"We are pleased with the additional data presented today suggesting that our NF-kappaB Decoy significantly reduces the inflammatory response associated with inflammatory bowel disease," said Leslie M. McEvoy, Ph.D., senior vice president of research at Corgentech. "Based on these data, we believe that NF-kappaB Decoy could someday have therapeutic potential as a novel cross-functional drug in both Crohn's disease and ulcerative colitis. IBD represents a new therapeutic target for NF-kappaB Decoy that, similar to atopic dermatitis where we currently have trials underway, represents a significant unmet medical need."

About Corgentech

Corgentech is a biopharmaceutical company focused on the development and commercialization of DNA-based novel therapeutics for significant unmet medical needs. We are creating a pipeline of novel therapeutics focused initially on the treatment of inflammatory diseases, infectious diseases and cancer. For more information on the company and its technologies, please visit www.corgentech.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Act of 1995. These include without limitation all statements related to our clinical trials and progress with developing product candidates. Words such as "believes," "anticipates," "plans," "expects," "intend," "will," "slated," "goal" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon our current expectations. Forward-looking statements involve risks and uncertainties. Our actual results and the timing of events could differ materially from those anticipated in such forward- looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to the development of NF-.B Decoy, progress, timing and results of our clinical trials for NF-.B Decoy, intellectual property matters, difficulties or delays in obtaining regulatory approval, manufacturing our product candidates, competition from other pharmaceutical or biotechnology companies, our ability to obtain additional financing to support its operations and other risks detailed in relevant filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K/A for the year ended December 31, 2004, and our quarterly report on 10-Q for the quarter ended March 31, 2005. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and Corgentech undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.

SOURCE Corgentech Inc.

Jennifer Cook Williams, Senior Director, Investor Relations, of Corgentech Inc.,
+1-650-624-9600, or [email protected]

http://www.prnewswire.com

News Provided by COMTEX